Q32 Bio Inc. (NASDAQ:QTTB) Given Consensus Rating of “Hold” by Analysts

Shares of Q32 Bio Inc. (NASDAQ:QTTB) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $24.86.

QTTB has been the topic of several research reports. Guggenheim lowered Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Oppenheimer dropped their target price on Q32 Bio from $80.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Leerink Partnrs lowered Q32 Bio from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $16.00 target price (down from $95.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Finally, BMO Capital Markets lowered Q32 Bio from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $22.00 to $3.00 in a research report on Tuesday, February 11th.

Q32 Bio Stock Performance

QTTB stock opened at $1.90 on Wednesday. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.61. The firm has a market cap of $23.14 million, a P/E ratio of -0.13 and a beta of -0.27. Q32 Bio has a 12-month low of $1.89 and a 12-month high of $53.79. The stock’s 50 day simple moving average is $2.93 and its 200 day simple moving average is $23.59.

Q32 Bio (NASDAQ:QTTB) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.25) by $0.09. As a group, equities research analysts predict that Q32 Bio will post -12.32 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio acquired a new position in shares of Q32 Bio during the fourth quarter valued at $26,000. Squarepoint Ops LLC acquired a new position in shares of Q32 Bio during the fourth quarter valued at $65,000. Two Sigma Investments LP acquired a new position in shares of Q32 Bio during the fourth quarter valued at $183,000. Trustees of Columbia University in the City of New York acquired a new position in shares of Q32 Bio during the fourth quarter valued at $461,000. Finally, Sanofi acquired a new position in shares of Q32 Bio during the fourth quarter valued at $840,000. 31.32% of the stock is owned by institutional investors and hedge funds.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.